DK452289A - Praeparat eller system til behandling af diabetes - Google Patents

Praeparat eller system til behandling af diabetes Download PDF

Info

Publication number
DK452289A
DK452289A DK452289A DK452289A DK452289A DK 452289 A DK452289 A DK 452289A DK 452289 A DK452289 A DK 452289A DK 452289 A DK452289 A DK 452289A DK 452289 A DK452289 A DK 452289A
Authority
DK
Denmark
Prior art keywords
insulin
function
liver
targeted
encapsulated
Prior art date
Application number
DK452289A
Other languages
Danish (da)
English (en)
Other versions
DK452289D0 (da
Inventor
Walter Blair Geho
Original Assignee
Technology Unlimited Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technology Unlimited Inc filed Critical Technology Unlimited Inc
Publication of DK452289D0 publication Critical patent/DK452289D0/da
Publication of DK452289A publication Critical patent/DK452289A/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14Liposomes; Vesicles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Birds (AREA)
  • Diabetes (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK452289A 1988-01-13 1989-09-13 Praeparat eller system til behandling af diabetes DK452289A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/143,180 US4863896A (en) 1984-05-03 1988-01-13 Diabetic control by combined insulin forms
PCT/US1988/001536 WO1989006540A1 (en) 1988-01-13 1988-05-13 Diabetic control by combined insulin forms

Publications (2)

Publication Number Publication Date
DK452289D0 DK452289D0 (da) 1989-09-13
DK452289A true DK452289A (da) 1989-11-09

Family

ID=22502938

Family Applications (1)

Application Number Title Priority Date Filing Date
DK452289A DK452289A (da) 1988-01-13 1989-09-13 Praeparat eller system til behandling af diabetes

Country Status (8)

Country Link
US (1) US4863896A (de)
EP (1) EP0358709B1 (de)
AT (1) ATE78169T1 (de)
AU (1) AU622370B2 (de)
DE (1) DE3872878T2 (de)
DK (1) DK452289A (de)
FI (1) FI894376A0 (de)
WO (1) WO1989006540A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420108A (en) * 1992-09-14 1995-05-30 Shohet; Isaac H. Method of controlling diabetes mellitus
WO1999016425A1 (en) * 1997-09-30 1999-04-08 The Ohio State University Lipid-modified insulin incorporated liposomes for selectively delivering cytotoxic agents to hepatoma cells
US7169410B1 (en) * 1998-05-19 2007-01-30 Sdg, Inc. Targeted liposomal drug delivery system
US6159931A (en) * 1998-09-29 2000-12-12 The Ohio State University Lipid-modified insulin incorporated liposomes for selectively delivering cytotoxic agents to hepatoma cells
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
AU2003236521A1 (en) * 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
CA2511530C (en) 2003-01-06 2013-07-09 Emisphere Technologies, Inc. Night-time oral insulin therapy
US20050203001A1 (en) 2004-03-05 2005-09-15 Emisphere Technologies, Inc. Oral insulin therapies and protocol
CN1849112B (zh) * 2003-09-09 2012-06-13 吉里德科学公司 治疗性脂质体
BRPI0513508B1 (pt) * 2004-07-19 2021-06-01 Biocon Limited Conjugados de insulina-oligômero, formulações e usos desses
WO2006127361A2 (en) 2005-05-23 2006-11-30 Sdg, Inc. Lipid construct for delivery of insulin to a mammal
US20110135725A1 (en) 2005-05-23 2011-06-09 Sdg, Inc. Lipid Construct for Delivery of Insulin to a Mammal
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
JP5868594B2 (ja) 2007-10-16 2016-02-24 バイオコン・リミテッドBiocon Limited 経口投与可能な固形医薬組成物及びそのプロセス
WO2010080976A1 (en) * 2009-01-09 2010-07-15 Sdg, Inc. (An Ohio Corporation) Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
CA2750223A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
KR101635689B1 (ko) 2009-01-28 2016-07-01 스마트쎌스, 인크. 제어 약물 전달을 위한 접합체 기재 시스템
US8906850B2 (en) 2009-01-28 2014-12-09 Smartcells, Inc. Crystalline insulin-conjugates
US8569231B2 (en) 2009-03-20 2013-10-29 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
EP2408808A4 (de) 2009-03-20 2015-05-06 Smartcells Inc Terminal-funktionalisierte konjugate und ihre verwendung
EP2598522A4 (de) 2010-07-28 2014-11-12 Smartcells Inc Rekombinante lektine, bindungsstellenmodifizierte lektine und anwendungen davon
AU2011282977A1 (en) 2010-07-28 2013-02-21 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
WO2012015692A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
TW201605470A (zh) 2013-10-04 2016-02-16 默沙東藥廠 葡萄糖反應性胰島素結合物
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
WO2018169954A1 (en) 2017-03-13 2018-09-20 Sdg, Inc. Lipid-based nanoparticles with enhanced stability
WO2020210697A1 (en) * 2019-04-12 2020-10-15 Sdg, Inc. Lipid-based nanoparticles and use of same in optimized insulin dosing regimens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377567A (en) * 1978-10-02 1983-03-22 The Procter & Gamble Company Lipid membrane drug delivery
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system

Also Published As

Publication number Publication date
DK452289D0 (da) 1989-09-13
ATE78169T1 (de) 1992-08-15
EP0358709A4 (de) 1990-03-08
US4863896A (en) 1989-09-05
EP0358709A1 (de) 1990-03-21
AU1790588A (en) 1989-08-11
WO1989006540A1 (en) 1989-07-27
AU622370B2 (en) 1992-04-02
EP0358709B1 (de) 1992-07-15
FI894376A0 (fi) 1989-09-15
DE3872878T2 (de) 1992-12-03
DE3872878D1 (de) 1992-08-20

Similar Documents

Publication Publication Date Title
DK452289A (da) Praeparat eller system til behandling af diabetes
DK0527835T3 (da) Doseringsform til afgivelse af et anti-Parkinsonmiddel
DK0480934T3 (da) Lægemiddel, der indeholder ephedrin og koffein til behandling af overvægt
FI875533L (fi) Insulinpreparat foer non-parenteral dosering.
FI880409A0 (fi) Transdermalt absorberande doseringsenhet foer estradiol och andra estrogena steroider och administrationsfoerfarande.
SE9401406L (sv) Farmaceutiska produkter för att bota tumörsjukdomar samt förfarande för framställning av desamma
ATE96308T1 (de) Dosierform fuer verabreichung in der humanmedizin.
NZ334270A (en) Glucagon like peptide (GLP-1), analogs and derivatives to treat post surgical catabolic changes and insulin resistance
DK1011653T3 (da) Anvendelse af xanthophyller i medikamenter til forbedring af varigheden af muskelfunktion eller behandling af muskelforstyrrelser eller -lidelser
ATE238778T1 (de) Transdermales therapeutisches system zur abgabe von hormonen
ES2107511T3 (es) Procedimiento para la preparacion de un concentrado de factor xi de la coagulacion sanguinea con alta actividad especifica, apropiado para su uso terapeutico.
SE8204874L (sv) Farmaceutiska preparat, innefattande humant insulin och humant proinsulin
Gray et al. Protective effect of pitressin and epinephrine against total body X-irradiation
KR910005858A (ko) 지방산 요법
PT651654E (pt) Utilizacao de um dimero de lisozima para a preparacao de um medicamento para modular os mecanismos natutais de defesa
AR003979A1 (es) Administracion transdermica de vorozol.
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
KR870010871A (ko) 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법
RU94006632A (ru) Способ лечения неспецифического язвенного колита
DK1007085T3 (da) Anvendelse af væksthormon i præparater til behandling af insulin-resistens i hjertet
ATE66375T1 (de) Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von verschiedenen erkrankungen des menschen in niedriger dosierung.
Kobrine et al. Further studies on histamine in spinal cord injury and post traumatic hyperemia
SE9101341D0 (sv) New medicinal use
KR900701311A (ko) 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법
SE8204872D0 (sv) Farmaceutiska preparat, innefattande humant insulin, human c-peptid och humant proinsulin

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment